Status:
RECRUITING
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Major Depressive Episode
Borderline Personality Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This neuroimaging study is a clinical trial investigating the effectiveness of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) in reducing s...
Detailed Description
This neuroimaging study aims to determine the effectiveness of iTBS-TMS to the IPL in reducing suicide risk in patients with MDE or BPD. This study also aims to identify the structural and functional ...
Eligibility Criteria
Inclusion
- 18-65 years of age
- Diagnosed with BPD or MDE
- Chief complaint of suicidal thoughts and behaviors
Exclusion
- Neurological conditions with known structural brain lesion
- Prior neurosurgical procedure
- Metal in the body that is ferromagnetic or metal injury to the eyes
- Epilepsy
- Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, or ventriculo-peritoneal shunt
- Psychopathology not appropriate for the treatment (e.g., manic episode or psychosis)
- Current alcohol dependence or active symptoms of non-alcohol psychoactive substance use withdrawal, as indicated by self-report
- Inability to meet the safety criteria for MRI scanning according to the protocols of the MGH Department of Radiology
- Current pregnancy
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04130958
Start Date
November 1 2023
End Date
April 30 2026
Last Update
June 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02129